Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance
Matinas BioPharma (NYSE American: MTNB) said it received a June 24, 2026 NYSE American notice for non-compliance with continued listing equity standards. The company reported stockholders’ equity of $3.02 million as of March 31, 2026 and losses in five of its last fiscal years, and previously $4.83 million as of Dec. 31, 2025. NYSE American accepted its May 4, 2026 compliance plan, granting a plan period through Oct. 2, 2027, with quarterly monitoring; delisting proceedings could follow if progr
How this was made
The 30-second read
Why it matters
MTNB is now in NYSE American Section 1009 procedures with a plan period through Oct 2, 2027, during which it must show progress and will face quarterly monitoring; failure could trigger delisting proceedings.
Market read
This is a concrete exchange compliance development that extends listing but keeps delisting risk alive, likely affecting risk premia and financing expectations.
What to watch
Investors should separate compliance mechanics from clinical/product timelines (e.g., MAT2203 development), since the exchange notice does not change SEC reporting or ongoing operations.
Background
NYSE American requires minimum stockholders’ equity thresholds for companies with losses; MTNB is below the $4.0M and $6.0M thresholds tied to different loss-history tests.
Ticker impact
Matinas BioPharma received an NYSE American notice for non-compliance with equity continued-listing standards and got a plan period through Oct 2, 2027.
Near-term downside bias from delisting overhang; volatility likely increases around quarterly compliance reviews and any financing needed to rebuild equity.
The filing is a fresh exchange compliance notice with a defined plan period deadline and explicit risk of delisting proceedings if the company fails to make consistent progress.
Market effects
Highlights ongoing capital/financing pressure for small-cap biopharma issuers with persistent losses and thin equity buffers.
Primarily impacts US micro/small-cap sentiment on NYSE American compliance risk.
Limited direct global spillover; relevant mainly to investors tracking US listing standards and biotech credit/liquidity risk.
Counterpoint
The notice explicitly states no immediate impact on trading and that the NYSE accepted the company’s plan, which can reduce immediate delisting fears versus worst-case outcomes.
Key entities
- companyMatinas BioPharma Holdings, Inc.
Subject of the NYSE American continued listing non-compliance notice and accepted compliance plan.
- regulator/exchangeNYSE American LLC
Issued the non-compliance notice and accepted the company’s plan, granting a plan period through Oct 2, 2027.
- product/programMAT2203
Biopharma pipeline asset described in the release; not directly tied to the listing compliance decision in the text.
